中美双批!恒赛生物KSD-101注射液临床开发进程再提速
4142026年3月9日,恒赛生物KSD-101注射液获中国国家药监局药品审评中心(CDE)临床试验默示许可(IND获批),适应症为“经标准治疗无效的EBV相关血液肿瘤”,标志着中国首个获得美国FDA IND批件、中国首个获得FDA快速通道资格(FTD)认定的原创树突细胞疫苗(DC疫...
View detailsSearch the whole station

preamble
The dragon is in full bloom, welcoming the spring, and the elites are gathering for the annual event. Looking back to 2023, it is to overcome difficulties and move forward; looking forward to 2024, it is to compete with a hundred boats and oar first. Accompanied by the spring breeze in April, Hengsai Bio held the 2024 Annual Meeting and Spring Tour Group Building Activity in Anji, Zhejiang Province.

Spring Overture
annual feast
On April 12, all the staff started the annual meeting trip in a relaxed and happy atmosphere. Shanghai headquarter and Wuhan clinical team met triumphantly, and kicked off the annual meeting with a feast. The staff members shared their true feelings with each other in a big group of wine, and sang the song of spring after tea and dinner.

Unity
Unlimited Vitality
In the warm spring breeze, the team carried out a series of fun and interactive games. Shiatsu board sports challenge let everyone quickly into the collective, exercise physical and mental, release vitality. Dragons fetch water to test the trust and tacit understanding between team members, the magic pen Ma Liang enhanced the team's coordination ability, you than I guess it is closer to the team's ideological distance. In the laughter, team members improved their understanding of each other, experienced the power of teamwork, and were confident to work together to meet more challenges in the future.
Concentration
Building the Dream

On April 13th, at the company's annual summary meeting, Dr. Liu Huining, Founder and CEO of Hengsai Biologicals, reviewed the significant progress of the company in the past year, thanked the team members for their collaboration and hard work, and shared the company's work plan for the year 2024, which is to focus on the development and industrialization of dendritic cell vaccines and the development and commercialization of dendritic cell vaccines. The company will continue to focus on dendritic cell vaccine development and industrialization.

Co-founder Mr. Cheng Xiangguo reiterated the company's values and explained in depth the corporate vision of gathering the spirit of a hundred rivers, stimulating the potential of cells, empowering healers, and creating a team of grandeur, which further enhanced the team members' sense of identification with the corporate culture.
Looking back, we are proud of the way forward;
Based on the present moment, we work together in the wind and rain, breaking the waves forward;
As we look to the future, we always look forward with enthusiasm and fearlessness;
We believe that Hengsai Bio will ride the waves and sail far away.
Springtime is in full bloom.
Enjoy the fjord

concluding remarks
The Kaiju is not as far away as the mountains and the seas.
Ride the momentum, not the days and months.
2026年3月9日,恒赛生物KSD-101注射液获中国国家药监局药品审评中心(CDE)临床试验默示许可(IND获批),适应症为“经标准治疗无效的EBV相关血液肿瘤”,标志着中国首个获得美国FDA IND批件、中国首个获得FDA快速通道资格(FTD)认定的原创树突细胞疫苗(DC疫...
View details1. PURPOSE This document describes KOUSAI´s position, and reflects our Corporate Policy on how patients in medical need may be able to access our new medicines before they are fully approved for use on prescription. 2. This document describes KOUSAI´s position and reflects our Corporate Policy on how patients in medical need may be able to access our new medicines before they are fully approved for use on prescription. 2. SCOPE We cover ...
View detailsDC Vaccine for Nasopharyngeal Carcinoma [Medium Swelling] Completes First Patient Enrollment for Dosing
View detailsHengsai Biologicals Completes Tens of Millions of Dollars in Series A+ Financing
View details